RxDoctor Payments Data

John Kendrick, MD

Vascular Surgery · Columbia, TNNPI 1265621635

Payments from drug & device makers

What this record shows

39 manufacturers reported payments, led by Medtronic at 41.9% of the total. Reporting peaked in 2019 at $7,333 and has fallen 93.1% since, to $508 in 2025.

$15,598in general payments, 2019–2025

Across 279 payments — averaging $55.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$7K
  • Cardiovascular Systems Inc.$3K
  • Bard Peripheral Vascular, Inc.$2K
  • Philips North America LLC$732
  • Silk Road Medical, Inc.$469
  • Penumbra, Inc.$377
  • plus $3K from 33 others

What the payments were for

  • Travel & lodging$8,76356%
  • Food & beverage$6,83544%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,598 in reported general payments places this provider in the 75th percentile of 117 vascular surgery providers in Tennessee.

See all vascular surgery providers in Tennessee

Medicare billing

Part B allowed, 2024
$1,046,937
Medicare patients
671
Services billed
2,455

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban82$76,386
XareltoRivaroxaban36$28,528
ClopidogrelClopidogrel Bisulfate308$3,422
Atorvastatin Calcium16$335
Cilostazol15$310
Pravastatin Sodium27$208
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen53$130
Pantoprazole Sodium15$79
Prednisone14$13

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$14$76,38682 claims
Johnson & JohnsonXarelto$53$28,52836 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 117 vascular surgery providers in Tennessee.

Other vascular surgery in Columbia

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →